Construction of subunit-based DNA vaccines against tuberculosis using five different Mycobacterium specific genes

Muhammad Mohsin Zaman, Mirza Imran Shahzad, Aeman Jilani, Areeba Yousaf, Ansah Bashir, Saher Riaz, Gildardo Rivera

Abstract


Background: Tuberculosis remains the major infectious and contagious disease with respect to morbidity and mortality around the globe. The main etiological agent of TB is Mycobacterium tuberculosis (M. tb). The cure and/or control of this disease is getting difficult day by day especially due to emergence of drug resistant strains, HIV co-infection and unavailability of good vaccines. BCG is the only available and permitted vaccine against TB, which has variable efficacy only limited to childhood. Therefore, new, well defined, antigen specific and state of the art Molecular Biology based DNA vaccines are required.

Methods: The current study is designed to develop subunit-based DNA vaccines against tuberculosis by using five different Mycobacterium specific genes, namely Rv1908c/KatG, Rv0350/DnaK, Rv0440/GroEL2, Rv0934/PstS and Rv3418c/GroES. All the selected genes were amplified through PCR and cloned into mammalian expression pVAX1 vector.

Results: All the transformed constructs were confirmed through restriction digestion, colony PCR and sequence analysis. These constructs will be used for various in Vivo immunization studies and also for the challenge studies against TB in future experiments.

Conclusion: DNA vaccines, alone or in combination with BCG, have enough potential to be a good therapeutic tool for TB and reduce the treatment time in future.

Keywords: DNA vaccine; pVAX1; Tuberculosis; Vaccines  


Full Text:

PDF

References


Whitlow E, Mustafa AS, Hanif SNM. An Overview of the Development of New Vaccines for Tuberculosis. Vaccines, (2020); 8(4): 586.

Organization WH (2021) Global Tuberculosis Report 2020. Geneva, Switzerland; WHO; 2021. ISBN 978-92-4-003702-1.

MacNeil A, Glaziou P, Sismanidis C, Date A, Maloney S, et al. Global epidemiology of tuberculosis and progress toward meeting global targets—worldwide, 2018. Morbidity and Mortality Weekly Report, (2020); 69(11): 281.

Lu J, Wang C, Zhou Z, Zhang Y, Cao T, et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clinical

and Developmental Immunology, (2011); 2011(1): 1-10.

Tang D-c, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature, (1992); 356(6365): 152-154.

Huygen K. Plasmid DNA vaccination. Microbes and infection, (2005); 7(5-6): 932-938.

Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine, (2009); 27(33): 4412-4423.

Montagnani C, Chiappini E, Galli L, de Martino M. Vaccine against tuberculosis: what’s new? BMC infectious diseases, (2014); 14(1): 1-9.

Arroyo L, Marín D, Franken KL, Ottenhoff TH, Barrera LF. Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia. BMC Infectious Diseases, (2018); 181-9.

Hamada Y, Cirillo DM, Matteelli A, Penn-Nicholson A, Rangaka MX, et al. Tests for tuberculosis infection: landscape analysis. European Respiratory Journal, (2021); 58(5).

Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, et al. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. The lancet Respiratory medicine, (2019); 7(9): 757-770.

Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. The lancet Respiratory medicine, (2015); 3(12): 953-962.

Bello S, Afolabi RF, Ajayi DT, Sharma T, Owoeye DO, et al. Empirical evidence of delays in diagnosis and treatment of pulmonary tuberculosis: systematic review and meta-regression analysis. BMC public health, (2019); 19(1): 1-11.

Mu J, Jeyanathan M, Small C-L, Zhang X, Roediger E, et al. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Molecular Therapy, (2009); 17(6): 1093-1100.

Mobed A. DNA Based vaccines against Mycobacterium tuberculosis: recent progress in vaccine development and delivery system. Iranian Journal of Immunology, (2020); 17(4): 255-274.

Kowalewicz-Kulbat M, Locht C. Recombinant BCG to enhance its immunomodulatory activities. Vaccines, (2022); 10(5): 827.

Arlehamn CSL, Lewinsohn D, Sette A, Lewinsohn D. Antigens for CD4 and CD8 T cells in tuberculosis. Cold Spring Harbor perspectives in medicine, (2014); 4(7): a018465.

Buzitskaya Z, Stosman K, Khairullin B, Kassenov M, Nurpeisova A, et al. A new intranasal influenza vector-based vaccine TB/FLU-04L against tuberculosis: preclinical safety studies. Drug Research, (2022); 72(05): 255-258.

Fomsgaard A, Liu MA. The key role of nucleic acid vaccines for one health. Viruses, (2021); 13(2): 258.

Chung C, Niemela SL, Miller RH. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proceedings of the National Academy of Sciences, (1989); 86(7): 2172-2175.

Sefidi-Heris Y, Jahangiri A, Mokhtarzadeh A, Shahbazi M-A, Khalili S, et al. Recent progress in the design of DNA vaccines against tuberculosis. Drug Discovery Today, (2020); 25(11): 1971-1987.

Fan X, Gao Q, Fu R. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiological research, (2009); 164(4): 374-382.

Ilghari D, Lightbody KL, Veverka V, Waters LC, Muskett FW, et al. Solution structure of the Mycobacterium tuberculosis EsxG· EsxH complex: functional implications and comparisons with other M. tuberculosis Esx family complexes. Journal of Biological Chemistry, (2011); 286(34): 29993-30002.

Shahzad MI, Shahid N, Sial N, Hasanat A, Khalid M, et al. Evaluation of DNA vaccines encoding M. Tb gene Bfrb and Mpt32 in mice model. Pakistan journal of pharmaceutical sciences, (2017); 30(5 (Supplementary)): 2025-2029.

Shahzad MI, Khan IH, Luciw PA, Gulfraz M, Khanum A. Cloning, Expression and Genetic Immunization Studies of Mycobacterium tuberculosis Gene esat6. Pakistan Journal of Zoology, (2013); 45(3).

Shahzad M. DNA vaccine against tuberculosis by using five Mycobacterium specific genes. International Journal of Mycobacteriology, (2021); 10(5): 4-4.

Munir A, Wilson MT, Hardwick SW, Chirgadze DY, Worrall JA, et al. Using cryo-EM to understand antimycobacterial resistance in the catalase-peroxidase (KatG) from Mycobacterium tuberculosis. Structure, (2021); 29(8): 899-912. e894.

Lopes RL, Borges TJ, Araújo JF, Pinho NG, Bergamin LS, et al. Extracellular mycobacterial DnaK polarizes macrophages to the M2-like phenotype. PLoS One, (2014); 9(11): e113441.

Vinod V, Pushkaran AC, Kumar A, Mohan CG, Biswas R. Interaction mechanism of Mycobacterium tuberculosis GroEL2 protein with macrophage Lectin-like, oxidized low-density lipoprotein receptor-1: An integrated computational and experimental study. Biochimica et Biophysica Acta (BBA)-General Subjects, (2021); 1865(1): 129758.

Esparza M, Palomares B, García T, Espinosa P, Zenteno E, et al. PstS‐1, the 38‐kDa M ycobacterium tuberculosis Glycoprotein, is an Adhesin, Which Binds the Macrophage Mannose Receptor and Promotes Phagocytosis. Scandinavian journal of immunology, (2015); 81(1): 46-55.

Maurya VK, Singh K, Sinha S. Suppression of Eis and expression of Wag31 and GroES in Mycobacterium tuberculosis cytosol under anaerobic culture conditions, (2014); 52(08): 773-780.

Ofori-Anyinam N, Hamblin M, Coldren ML, Li B, Mereddy G, et al. KatG catalase deficiency confers bedaquiline hyper-susceptibility to isoniazid resistant Mycobacterium tuberculosis. bioRxiv, (2023); 2023.2010. 2017.562707.

LI X, XIAO T, LI M, LIU H, LI S, et al. Evaluation of the antigenicity of Dnak and MPT83 proteins of Mycobacterium tuberculosis. Chinese Journal of Microbiology and Immunology, (2019); 106-113.

an X, Li X, Wan K, Zhao X, Deng Y, et al. Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis. Vaccine, (2021); 39(47): 6860-6865.




DOI: http://dx.doi.org/10.62940/als.v11i3.1902

Refbacks

  • There are currently no refbacks.